8 Amendments of Ignazio CORRAO related to 2018/0225(COD)
Amendment 60 #
Proposal for a decision
Recital 8 a (new)
Recital 8 a (new)
(8a) The programme should provide a comprehensive vision for research and product development to ensure increased coordination and coherence of European programmes with national and international initiatives and research agendas, and to ensure promising products are supported throughout the entire development pipeline, especially in areas with no market interest.
Amendment 61 #
(9a) The work programme for a given call under the pillar ‘Global Challenges and Industrial Competitiveness’ could allow grants for large-scale product validation and market replication, recognizing this is of specific important in areas with market failure, poverty-related and neglected diseases.
Amendment 123 #
Proposal for a decision
Annex I – part II – point 1 – point 1.1 – paragraph 4
Annex I – part II – point 1 – point 1.1 – paragraph 4
These health challenges are complex, interlinked and global in nature and require multidisciplinary, cross-sectorial and transnational collaborations. Research and innovation activities will build close linkages between discovery, clinical, epidemiological, environmental and socio- economic research as well as with regulatory sciences. They will harness the combined skills of academia, not-for-profit product developers and industry and foster their collaboration with health services, patients, policy-makers and citizens in order to leverage on public funding and ensure the uptake of results in clinical practice as well as in health care systems. They will foster strategic collaboration at EU and international level in order to pool the expertise, capacities and resources needed to create economies of scale, scope and speed as well as to share the expected benefits and financial risks involved.
Amendment 129 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 1
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 1
Protecting people against cross-border health threats and poverty-related and neglected diseases is a major challenge for public health, calling for effective international cooperation at EU and global level. This will involve as well as coordination between EU funding instruments in R&I and international development. This will involve developing tools for prevention, preparedness, early detection, treatment and cure of infectious diseases, and also tackling antimicrobial resistance (AMR) following a ‘One Health approach’.
Amendment 132 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 3
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 3
– VNew development and optimisation of vaccines, diagnostics, treatments and cures for infectious diseases, including co- morbidities and co-infections with priority for poverty-related and neglected diseases where commercial markets are lacking;
Amendment 135 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 5
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 5
– Barriers to the implementation and uptake of medical interventions in clinical practice as well as in the health system, including regulatory strengthening in low-and middle-income countries;
Amendment 139 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 6
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 6
– Trans-border aspects and research and product development in of infectious diseases and specific challenges in low- and middle-income countries (LMICs), such as tuberculosis, HIV and malaria as well as neglected tropical diseases.
Amendment 164 #
Proposal for a decision
Annex I – part II – point 6 – point 6.2 – point 6.2.2 – paragraph 2 – point 1 – indent 5
Annex I – part II – point 6 – point 6.2 – point 6.2.2 – paragraph 2 – point 1 – indent 5
– Research on newly emerging health issues and health threats, large scale epidemics of infectious diseases and health threats with special attention for the threat of antimicrobial resistance.